The company is a clinical-stage biopharmaceutical firm discovering and developing novel precision peptide therapies for endocrine and metabolic disorders using its proprietary Precision Endocrine Peptide (PEP) platform technology. Its pipeline includes canvuparatide for chronic hypoparathyroidism, a long-acting GLP-1/GIP co-agonist for obesity, and imapextide for post-bariatric hypoglycemia—all engineered to overcome limitations of existing peptide therapies by delivering extended duration of action, stable drug concentrations, and less frequent dosing. The company generates value by developing and potentially commercializing these therapies to address large patient populations with significant unmet medical needs, planning to build internal sales capabilities for specialized indications while pursuing partnerships in larger markets.